© 2022 MJH Life Sciences and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
© 2022 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Thomas E. Hutson, DO, PharmD, shares insight on the role of combination therapy and recent advances for the management of renal cell carcinoma.
June 29th 2021
Thomas E. Hutson, DO, PharmD, provides insight on the diagnosis of renal cell carcinoma (RCC) and discusses classic signs and symptoms of the disease.
An expert in urologic oncology reviews the staging, grade, and types of renal cell carcinoma.
July 6th 2021
Kidney cancer expert, Dr Thomas E. Hutson, comments on treatment approaches for the management of renal cell carcinoma.
Thomas E. Hutson, DO, PharmD, discusses the historic and current goals of therapy for the treatment of RCC.
July 13th 2021
Dr Thomas E. Hutson shares insight on recent advances for the treatment of RCC including the role of and VEGF inhibitors, immune therapy, and mTOR inhibitors.
An expert in kidney cancer reviews the phase 3 CLEAR trial for frontline metastatic renal cell carcinoma.
July 20th 2021
Urologic oncology expert, Dr Thomas E. Hutson, reviews additional agents and clinical trials in the pipeline for the treatment of RCC.
Thomas E. Hutson, DO, PharmD, discusses his approach to determining the optimal initial therapy for a patient with RCC.
July 27th 2021
Kidney cancer expert, Dr Thomas E. Hutson, shares insight on managing adverse events resulting from combination therapy in RCC.
Dr Thomas E. Hutson comments on the rationale for using combination immune therapy, as well as a combination of immune therapy and an oral VEGF inhibitor for initial treatment of RCC.
I Was Preparing to Be an Oncology Nurse, That is Until My Sister's Cancer Returned
'There's a Gift in the Conflict' of Cancer, Says Patrick Dempsey
The Alphabet Soup of Medicare Is so Confusing
Sarclisa-Containing Treatment Regimen Shows ‘Remarkable’ Results for Relapsed Myeloma